4Go AS, Hylek EM, Phillips KA, et al. Prevalence of diag- nosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagula- tion and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375.
5Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-988.
6Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, inci- dence, prognosis, and predisposing conditions for atrial fibril- lation: population-based estimates. Am J Cardiol 1998; 82: 2N-9N.
7Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrom- boric therapy to prevent stroke in patients who have nonval- vular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
8Mant J, Hobbs FD, Fletcher K, et aL Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treat- ment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493-503.
9Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151: 297-305.
10Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689-2696.
